CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, announced that its Activ-Film™ technology was selected to protect a new SARS Rapid Antigen test for COVID-19 that recently received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
The QuickVue® SARS Antigen test is a point-of-care rapid antigen test developed by Quidel® Corporation, a leading manufacturer of diagnostic healthcare solutions, that delivers test results in 10 minutes. The visually read test requires no supplemental instrumentation and offers expanded access to affordable and accurate COVID-19 testing that will help meet the urgent testing needs of the global economy, including for those in school systems and rural areas.
Aptar CSP Technologies’ Activ-Film™ technology is integrated into the diagnostic kit to protect against moisture and other environmental conditions that could otherwise impact test accuracy. Activ-Film™ leverages Aptar’s proprietary 3-Phase Activ-Polymer™ technology, which provides a broad spectrum of custom-engineered protection in a variety of configurations, such as Activ-Vial™ for housing diagnostics dipsticks and Activ-Tab integrated within diagnostic cassettes. This material science-based active packaging technology is currently used to protect a range of electrochemical, lateral flow and molecular diagnostic test kits on the market today.
“We are pleased to partner with Quidel® Corporation on this critical diagnostic tool and help bring the QuickVue® SARS Antigen test to the market,” said Stephan B. Tanda, Aptar President and CEO. “Our material science Activ-Film™ technology protects the test strips, helping to provide quick, reliable results. We will continue to live up to our purpose and responsibility to society by providing solutions that protect critical COVID-19 diagnostic kits, along with dispensing solutions for medicines and consumer products needed by millions of people each day.”
Badre Hammond, Vice President Commercial Operations, Aptar CSP Technologies concluded, “As we continue to navigate through the COVID-19 crisis, this game-changing solution will help meet the urgent demand for COVID-19 testing in communities around the world. We are committed to leveraging our material science expertise to enable our partners to meet the ongoing need for innovative healthcare solutions that help improve and save lives.”
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, design, engineering and science to create dispensing, dosing and protective packaging technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: